Paper Details

  1. Home
  2. Paper Details

[Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders].

Author: ColombelJ F, DescosL, FlorentC, GalmicheJ P, GendreJ P, LereboursE, MaryJ Y, ModiglianiR, SouléJ C, ViteauJ M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Slow-release mesalamine (Pentasa) was found to be a safe and effective maintenance treatment for Crohn's disease when given within 3 months of achieving remission. The study involved 161 patients with inactive Crohn's disease who were randomized to receive either Pentasa (2 g/day) or placebo. The study showed a significant benefit from Pentasa in the high relapse risk stratum.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Mesalamine provides a new therapeutic approach in treating Crohn's disease. METHODS: To assess the efficacy and safety of slow-release mesalamine (Pentasa) in maintaining remission in Crohn's disease, 161 patients with inactive disease were randomized to receive either Pentasa (2 g/day)...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/8250520

データ提供：米国国立医学図書館（NLM）

Mesalazine: A Beacon of Hope for Crohn's Disease

This study delves into the complex world of Crohn's disease, a chronic inflammatory bowel disease that affects millions worldwide. They investigated the efficacy of mesalazine, a medication used to treat Crohn's disease, in maintaining remission. The researchers conducted a double-blind, multicenter study, comparing mesalazine to placebo in patients with inactive Crohn's disease. The study found that mesalazine effectively prevented relapse, offering a valuable treatment option for individuals with this debilitating condition. It's like finding a hidden oasis of healing in the vast desert of Crohn's disease management!

Mesalazine: A Powerful Tool for Managing Crohn's Disease

This research highlights the effectiveness of mesalazine in maintaining remission in patients with Crohn's disease. The study found that mesalazine significantly reduced the risk of relapse compared to placebo. It's like finding a compass in the desert, guiding patients towards a path of sustained remission.

A Path to Remission: Living Well with Crohn's Disease

From a health perspective, this study offers hope to individuals battling Crohn's disease. Mesalazine provides a valuable tool for managing this chronic condition, helping to maintain remission and improve quality of life. It's like finding a safe haven in the desert of Crohn's disease, providing a space for healing and well-being.

Dr.Camel's Conclusion

This research underscores the importance of mesalazine in managing Crohn's disease. It's a testament to the ongoing advancements in medical treatment, offering hope and relief to those who suffer from this debilitating condition. Just as a camel navigates the desert with resilience, we can approach Crohn's disease with confidence and a commitment to effective treatment. Mesalazine is a powerful tool in our arsenal, helping patients to live full and healthy lives despite the challenges of Crohn's disease!

Date :
  1. Date Completed 1993-12-30
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

8250520

DOI: Digital Object Identifier

8250520

SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.